Physician

Asim Ranjan Singh, M.D.

According to 2025 Medicare claims, Asim Singh, M.D. (NPI: 1306873914) practices nephrology in the Erie, PA market, with the plurality of this provider's patient population coming from Erie, PA. This provider's primary affiliated billing organization is BAYVIEW NEPHROLOGY, INC. (NPI: 1194761643; TIN: 251516103) and primary practice location at 16550-0002.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 451 traditional Medicare patients, billed 1,766 HCPCS/CPT codes, and received $147,489 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,162 prescription claims across 524 beneficiaries totaling $2,450,892 in drug costs, led by Krystexxa (Pegloticase). DME data shows 69 claims. Open Payments data shows 49 records totaling $1,044. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $210,212 to $147,489. In contrast, Part D prescription costs have risen steadily, from $184,446 to $2,450,892. For DME billing, this smaller-volume category changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	690	4,272	$210,212
2016	716	3,638	$243,661
2017	757	2,969	$241,713
2018	764	3,622	$321,277
2019	724	2,673	$244,019
2020	625	2,403	$210,957
2021	579	2,053	$192,264
2022	520	2,329	$181,713
2023	528	1,746	$141,640
2024	451	1,766	$147,489

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	300	2,464	$184,446
2016	345	2,586	$217,633
2017	389	2,851	$298,103
2018	461	3,117	$350,280
2019	421	2,963	$199,926
2020	361	2,500	$140,654
2021	368	2,641	$339,818
2022	476	3,003	$210,988
2023	531	3,303	$1,462,028
2024	524	3,162	$2,450,892

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	26	$1,317
2016	N/R	30	$1,219
2017	N/R	40	$1,298
2018	N/R	53	$1,382
2019	N/R	44	$984
2020	N/R	35	$1,298
2021	N/R	69	$1,960
2022	N/R	99	$3,266
2023	N/R	115	$3,626
2024	N/R	69	$2,123

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	135	168	$138
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	58	213	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	192	216	$66
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	158	757	$63
90935	Hemodialysis procedure with physician evaluation	67	159	$57

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Krystexxa	Pegloticase	33	896	$1,852,316
Jardiance	Empagliflozin	77	4,440	$87,705
Eliquis	Apixaban	39	1,650	$31,383
Veltassa	Patiromer Calcium Sorbitex	20	888	$20,055
Lokelma	Sodium Zirconium Cyclosilicate	18	810	$17,143

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7502	Cyclosporine, oral, 100 mg	N	N/R	12	$1,178
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	14	$336
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$320
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$288

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	49	$1,044	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Asim Ranjan Singh, M.D.?

Tedicare shows public-source Medicare data for Asim Ranjan Singh, M.D. (NPI 1306873914), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Asim Ranjan Singh, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Asim Ranjan Singh, M.D.?

Asim Ranjan Singh, M.D. is linked to BAYVIEW NEPHROLOGY, INC. (billing NPI 1194761643) in the available physician profile data.

Does Asim Ranjan Singh, M.D. have Open Payments data?

Asim Ranjan Singh, M.D. has 49 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.